AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Metrics to compare | AXIM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAXIMPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.5x | −2.4x | −0.6x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price / Book | −0.2x | 1.7x | 2.6x | |
Price / LTM Sales | 21.7x | 7.4x | 3.1x | |
Upside (Analyst Target) | - | 130.9% | 55.7% | |
Fair Value Upside | Unlock | 10.1% | 6.8% | Unlock |